Skip to content
PeptideAI
Human RCTlongevityrecoveryenergyblood sugar

Carnosine

A dipeptide concentrated in muscle and brain that buffers acid during hard efforts and mops up the reactive carbonyls that glycate proteins as you age.

Also known as L-carnosine, beta-alanyl-L-histidine, N-acetylcarnosine

Human RCT — Randomised controlled trials in humans, but not an approved product for this use.

Beta-alanine loading and muscle carnosine elevation are supported by a large body of randomised human trials and meta-analyses for high-intensity exercise performance — this is genuinely well-established. The anti-glycation and longevity side is supported mainly by in vitro and animal work; the fibroblast lifespan-extension result is real but has not translated into human outcome data.

How it works

Carnosine's imidazole ring has a pKa close to intramuscular pH, which makes it an unusually effective proton buffer exactly where and when lactic acidosis occurs — this is the basis of its performance effects, and it is why beta-alanine supplementation works, since beta-alanine is the rate-limiting precursor. Separately, carnosine reacts with reactive carbonyl species such as methylglyoxal and 4-hydroxynonenal, forming adducts and preventing those carbonyls from cross-linking proteins into advanced glycation end-products. It also chelates transition metals and has been shown to extend replicative lifespan in cultured human fibroblasts and to rejuvenate senescent-looking cells morphologically. The catch is bioavailability: oral carnosine is largely cleaved by serum carnosinase into beta-alanine and histidine before reaching tissue, which is why loading beta-alanine to raise endogenous synthesis is generally the more effective strategy in practice.

Targets: Intramuscular pH buffering, Reactive carbonyl species (methylglyoxal, 4-HNE), Advanced glycation end-product formation, Transition metal chelation

Dosing

ProtocolDoseFrequencyRoute
Oral carnosineWith food.500 mg – 1000 mgonce or twice dailyoral
Beta-alanine loading (the effective route to muscle carnosine)Split through the day to limit paraesthesia.3200 mg – 6400 mgdaily, split into 800-1600 mg dosesoral
  • · 500-1000 mg per dose. Understand that most of this is degraded by serum carnosinase — the anti-glycation rationale is better than the muscle-loading rationale for oral carnosine.
  • · 3.2-6.4 g/day of beta-alanine for 4-10 weeks raises muscle carnosine 40-80%. This is one of the best-evidenced ergogenic protocols in sports nutrition, and it is what actually gets carnosine into muscle.

Titration

Split beta-alanine into doses of 800-1600 mg or use a sustained-release form to avoid the harmless but unpleasant paraesthesia that comes with larger single doses.

Cycling

Beta-alanine loading is typically 4-10 weeks to saturate, then a maintenance dose of about 1.2 g/day. Muscle carnosine washes out slowly over roughly 6-15 weeks after stopping, so short cycles are pointless.

Work out your exact syringe units →

Pharmacology

Half-life
Plasma carnosine is cleared within roughly 1-2 hours by serum carnosinase. Muscle carnosine, by contrast, turns over on a scale of weeks — the loading and washout timeline of beta-alanine protocols is measured in months.
Onset
Performance effects from raising muscle carnosine require 4-10 weeks of consistent beta-alanine loading. Direct oral carnosine gives no meaningful acute effect.
Routes
oral, topical
Molecule
Endogenous dipeptide (beta-alanyl-L-histidine)
Sequence length
2 amino acids
Molecular weight
226.23 Da

Handling

Diluent
Not applicable — oral supplement
Lyophilised
Not applicable; capsules and powder stored dry at room temperature.
Reconstituted
Not applicable.

Mixing

Carnosine is not sold as an injectable in normal practice. N-acetylcarnosine is used as an ophthalmic drop for cataracts, which is a separate formulation entirely.

Side effects

  • very commonParaesthesia — tingling of face, scalp and hands from beta-alanine— Dose-dependent, harmless, and completely avoidable by splitting doses or using sustained-release.
  • uncommonMild gastrointestinal upset
  • uncommonReduced taurine levels with prolonged high-dose beta-alanine— Theoretical from transporter competition; has not shown clinical consequences in human trials.

Do not use if

  • Carnosinaemia and other rare disorders of histidine dipeptide metabolism.
  • Nothing else meaningful — this is one of the safest compounds on the site.

Combining it

  • cautiontaurine — Beta-alanine and taurine compete for the same transporter; high chronic beta-alanine may modestly lower taurine.
  • synergycreatine — Well-studied combination for high-intensity performance, buffering and phosphocreatine acting on different limits.

What to monitor

  • · No bloodwork required.
  • · For performance use, track work at a fixed high-intensity duration — carnosine's effect shows up in 1-4 minute efforts, not in one-rep maxes.

Legal status

Sold freely as a dietary supplement in the US, EU and most jurisdictions.

References

  • Meta-analyses of beta-alanine supplementation and high-intensity exercise performance (review)
  • Hipkiss, review of carnosine as an anti-glycation and anti-ageing agent (review)
  • Boldyrev et al., review of physiology and pathophysiology of carnosine (review)

Mechanism in depth

Carnosine's imidazole ring has a pKa of about 6.8, which is remarkably close to intramuscular pH during hard anaerobic work. That is not a coincidence of chemistry — it is why carnosine is concentrated in exactly the tissue where protons accumulate fastest, and it is what makes it an effective physiological buffer precisely in the window where lactic acidosis limits performance. This is the best-evidenced part of the compound and it is the mechanism behind the beta-alanine literature, since beta-alanine is the rate-limiting precursor for muscle carnosine synthesis. The performance signature follows directly from the mechanism: the benefit shows up in efforts lasting roughly one to four minutes, where proton accumulation is the binding constraint, and it does not show up in one-rep maxima or in long aerobic work. Recent meta-analytic work has also found no ergogenic effect on repeated-sprint ability specifically, which is consistent with that mechanism rather than contradicting it. The ageing side runs differently. Carnosine reacts with reactive carbonyl species — methylglyoxal, 4-hydroxynonenal — forming adducts and sacrificing itself to prevent those carbonyls from cross-linking proteins into advanced glycation end-products. It also chelates transition metals, limiting Fenton chemistry. In cultured human fibroblasts carnosine extended replicative lifespan and reversed the senescent morphology, which is a striking result that has never been shown to translate. The catch that ties both halves together is serum carnosinase: humans hydrolyse circulating carnosine far faster than the animals most of the anti-glycation work was done in, so the tissue exposure achieved by swallowing carnosine is much lower in a person than the preclinical data would suggest.

What usually goes wrong

The dominant error is taking oral carnosine and expecting the muscle-loading result. Serum carnosinase hydrolyses circulating carnosine efficiently in humans — more so than in most of the species the preclinical anti-glycation work was done in — so oral carnosine mostly delivers beta-alanine and histidine, expensively. If you want muscle carnosine, take beta-alanine; it is the rate-limiting precursor, it costs a fraction as much, and it is the intervention the randomised trials actually studied. The second error is expecting the wrong effect: carnosine buffers protons, so it helps in efforts of roughly one to four minutes. It does not improve one-rep maxima, and a 2026 meta-analysis of 17 trials found no benefit for repeated-sprint ability. If you are testing it on the wrong exercise you will conclude it does not work when the real problem is the instrument. The third is the paraesthesia — the tingling face and scalp from a large single beta-alanine serving is harmless, dose-per-serving dependent, and completely avoidable by splitting into 800-1600 mg portions or using sustained-release. People quit over it unnecessarily. The fourth is cycling too fast. Muscle carnosine takes four to ten weeks to saturate and washes out over six to fifteen weeks, so a four-week trial that you abandon has barely started, and an on-off cycling pattern makes no sense for a compartment with that turnover rate. The fifth is expecting the fibroblast lifespan-extension result to mean something for you: it is a real in vitro finding and it has never translated into human outcome data.

Titration ladder

  1. 1600 mgWeek 1 — 1.6 g/day of beta-alanine, split into two doses of 800 mg. Starting split is the whole point — paraesthesia is dose-per-serving dependent, not total-dose dependent, and a single large serving is what produces the face and scalp tingling people complain about.
  2. 3200 mgWeeks 2-3 — 3.2 g/day, split into four doses of 800 mg or two doses of 1600 mg depending on tolerance. This is the bottom of the effective loading range.
  3. 6400 mgWeeks 4-10 — Up to 6.4 g/day in fragmented doses if you tolerate it. Systematic review evidence supports fragmented dosing of 4-6.4 g/day over five to eight weeks as more effective than single large servings. Sustained-release formulations allow larger single servings without paraesthesia.
  4. 1200 mgWeek 10 onward — maintenance — Approximately 1.2 g/day maintains the elevated muscle carnosine once you are saturated. Muscle carnosine washes out slowly over roughly 6-15 weeks after stopping, which is why short cycles are pointless and why maintenance dosing is modest.

Bloodwork worth running

MarkerWhenWhy it matters
None requiredNot applicable — no routine testing is indicated.Carnosine and beta-alanine are among the safest compounds discussed on this site and no routine monitoring is established or necessary. Stating that plainly is more useful than inventing a panel.Act if: None.
Work completed at a fixed high-intensity duration (performance test, not bloodwork)Baseline before loading, then at four weeks and again at ten weeks. Same protocol, same time of day, similar fatigue state.The only endpoint that meaningfully tracks whether beta-alanine loading worked. Carnosine's effect appears in one-to-four-minute efforts, so a 2000 m row, a 1500 m run or a fixed-wattage time-to-exhaustion test is the right instrument. A one-rep max is the wrong instrument and will show nothing.Act if: Published trials report time-to-exhaustion improvements around 6.5% versus roughly 1.4% for placebo in trained runners after four weeks. No change at ten weeks of consistent loading means it is not working for you.
HbA1c, if using carnosine for the anti-glycation rationaleBaseline and at twelve weeks.Not because carnosine reliably moves it, but because the anti-glycation argument is about glycation burden and HbA1c is the accessible index of it. It sets the context for whether the rationale even applies to you.Act if: None specific. If your HbA1c is already excellent, the anti-glycation argument for supplementation is correspondingly weaker.

Pharmacokinetics

Tmax
2 h
Time to steady state
42 days
Crosses blood-brain barrier
partial
Accumulates
Yes — doses stack before steady state
Metabolism
Hydrolysis by serum carnosinase (CN1) to beta-alanine and histidine. Tissue carnosinase (CN2) handles intracellular turnover. Note that CN1 activity varies substantially between individuals on genetic grounds, which means oral carnosine bioavailability is genuinely person-specific.
Elimination
Renal excretion of carnosine and its constituent amino acids; a fraction of an oral dose appears intact in urine.

Receptor targets

  • Intramuscular proton buffering — Imidazole pKa approximately 6.8, matched to intramuscular pH during anaerobic work.

    Direct pH buffering in the exact physiological window that limits high-intensity performance. This is the mechanism with the strongest human evidence.

  • Reactive carbonyl species — methylglyoxal, 4-hydroxynonenal — Chemical adduct formation, not receptor binding.

    Sacrificial scavenging that prevents carbonyls from cross-linking proteins into advanced glycation end-products. The basis of the anti-ageing claim.

  • Transition metals — copper, zinc, iron — Chelation.

    Limits metal-catalysed Fenton chemistry and hydroxyl radical generation.

  • Serum carnosinase (CN1) — Substrate — efficiently hydrolysed.

    Not a therapeutic target but the reason oral carnosine underperforms in humans. CN1 activity varies genetically between individuals, so this is a real source of person-to-person variation in response.

  • TauT taurine transporter (competition by beta-alanine) — Beta-alanine and taurine compete for the same transporter.

    Theoretical reduction in tissue taurine with chronic high-dose beta-alanine. This has not shown clinical consequences in human trials.

Trials

  • Beta-alanine supplementation and time to exhaustion in competitive middle- and long-distance runners Randomised placebo-controlled trial · 4 weeks · 2025

    Time to exhaustion increased 6.5% with beta-alanine versus 1.4% with placebo (effect size d = 0.46) after four weeks of supplementation.

  • Beta-alanine and repeated sprint ability — systematic review and multilevel meta-analysis Systematic review and meta-analysis of 17 randomised controlled trials · 2026

    No statistically significant improvement in mean repeated-sprint performance (SMD = -0.018) or fatigue metrics with chronic beta-alanine supplementation. A clean negative result that is consistent with the buffering mechanism — repeated sprints are not the exercise domain carnosine helps.

  • Dosing strategies for beta-alanine supplementation in strength and power performance — systematic review Systematic review of nine studies · 2025

    Fragmented dosing of 4-6.4 g/day over five to eight weeks was more effective than single large servings. This is the evidence behind the split-dose titration ladder above.

What to expect, and when

Minutes to an hour after a beta-alanine dose: paraesthesia, if the serving was large. It peaks around 30-60 minutes and passes. It tells you the dose was absorbed and nothing else. Days one to seven: no performance effect. Muscle carnosine is barely moving yet. Weeks two to four: muscle carnosine begins to rise measurably; the earliest positive trials show effects around the four-week mark. Weeks four to ten: the loading window. Muscle carnosine rises roughly 40-80% across this period and this is where performance changes consolidate. Week ten onward: saturation; drop to a maintenance dose of about 1.2 g/day. After stopping: washout over roughly six to fifteen weeks, which is slow enough that a missed week costs you nothing. Direct oral carnosine, by contrast, produces no meaningful acute effect at any point.

Stacking and comparisons

Creatine is the classic and well-studied partner: creatine addresses phosphocreatine availability and carnosine addresses proton accumulation, so they limit different things and the combination is coherent for high-intensity work. Sodium bicarbonate is the more interesting pairing mechanistically — bicarbonate buffers extracellularly, carnosine buffers intracellularly, and a 2024 meta-analysis found the combination beneficial where neither showed an effect alone in that analysis. If you are chasing one-to-four minute performance, that is the stack with the best rationale. Taurine is the one to keep an eye on: beta-alanine and taurine compete for the same transporter, and chronic high-dose beta-alanine may modestly reduce tissue taurine. This has not produced clinical consequences in human trials, so it is a note rather than a warning, but if you are already supplementing taurine, take them at different times. Splitting doses or using a sustained-release formulation eliminates the paraesthesia entirely and is the single most useful practical tip for this compound. There are no meaningful drug interactions.

Against everything else on this page, carnosine and beta-alanine occupy a completely different evidence tier and it is worth saying so bluntly. Beta-alanine loading is supported by a large body of randomised human trials and meta-analyses, is listed among the small handful of genuinely evidence-based ergogenic aids, and costs almost nothing. Epitalon has a Russian cohort study; MOTS-c has mice; beta-alanine has a literature. Do not let the shared page flatten those into the same register. That said, the well-evidenced part is the performance part. The longevity and anti-glycation side of carnosine rests on in vitro and animal work — the fibroblast replicative lifespan extension is real and has not translated. Against oral carnosine specifically: beta-alanine wins decisively on cost, on bioavailability and on evidence. The only argument for oral carnosine is the anti-glycation one, where you want circulating carnosine rather than muscle carnosine, and even there serum carnosinase undercuts it. Against carnosinase-resistant analogues under development: those may eventually solve the human bioavailability problem, and none is available yet.

Rough cost

$10–$40/month. Not verified against live pricing this session. Beta-alanine powder at 3.2-6.4 g/day is one of the cheapest interventions discussed anywhere on this site — bulk powder costs a few cents per gram. Oral carnosine capsules at 500-1000 mg twice daily cost considerably more per month and deliver less to muscle, which is the whole argument. N-acetylcarnosine eye drops are a separate product with separate pricing.

Genuinely uncertain

  • The 2-hour tmax given is for plasma carnosine after an oral dose and is approximate; individual serum carnosinase activity varies genetically and substantially changes this.
  • Oral bioavailability of carnosine in humans has not been resolved to a single percentage and varies by CN1 genotype.
  • Volume of distribution, protein binding and clearance are not established as formal pharmacokinetic parameters.
  • The blood-brain barrier field is set to 'partial' because carnosine is present in brain tissue and there is transport literature, but I did not resolve a definitive human study on penetration of orally administered carnosine.
  • Time to steady state is given as 42 days, reflecting the 4-10 week muscle carnosine loading window rather than a plasma steady state — this is a tissue-loading figure, not a conventional pharmacokinetic one.
  • The 40-80% muscle carnosine elevation figure from beta-alanine loading is the commonly cited range from the sports nutrition literature; I did not resolve the specific primary source in this session.
  • The anti-glycation and longevity claims rest on in vitro and animal work with no human outcome data.
  • The taurine depletion concern is theoretical from transporter competition and has not shown clinical consequences in human trials.
  • Participant numbers for the individual trials cited were not resolvable from the abstracts available and are recorded as null rather than estimated.
  • Cost figures are estimates and were not verified against live pricing.

Papers